▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4139 by analyst upside · 2026-11-13
AMGN
Amgen Inc.
Healthcare · Market Cap $253B · P/E 27.1x
ANALYST PRICE TARGET
-7.5%
implied upside to consensus target
Current Price $467.06
Consensus Target $431.81
Bull Target $536.0
Bear Target $230.0
Analysts Covering 29
ANALYST CONSENSUS - HOLD
Strong Buy
3
Buy
6
Hold
15
Sell
5
52-Week Low $312.39
52-Week High $483.99
YTD Return +45.5%
FUNDAMENTALS
Market Cap $253B
P/E Ratio (TTM) 27.1x
Forward P/E 18.7x
EPS (TTM) $17.25
PEG Ratio 2.82
Dividend Yield 2.16%
Revenue (TTM) $38.9B
Profit Margin 24.1%
52-WEEK RANGE
52-Week Low $312.39
52-Week High $483.99
Current Price $467.06
Bear Target $230.0
Bull Target $536.0
● Now $467.06 ● Target $431.81
TRADING DATA
Avg Volume 2.8M
YTD Return +45.5%
Analyst Count 29
Consensus Hold
Upside to Target -7.5%
Last Updated 2026-11-13

ANALYST SUMMARY

Amgen Inc. (AMGN) is currently trading at $467.06 with a Wall Street consensus price target of $431.81, which is 7.5% below the current price over the next 12 months. 29 analysts currently cover AMGN, with a consensus rating of Hold - 31% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $536.0, while the most cautious has a target of $230.0.

AMGN operates in the Healthcare sector with a market capitalisation of $253B. The stock is up 45.5% year-to-date and is currently trading near the upper end of its 52-week range of $312.39 – $483.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Freedom Broker ↓ Downgrade
Buy → Hold 2026-11-06 Building track record
Leerink Partners - Reiterated
Market Perform → Market Perform 2026-11-05 29% win rate (7 calls)
Guggenheim - Reiterated
Neutral → Neutral 2026-11-05 62% win rate (8 calls)
Canaccord Genuity - Reiterated
Hold → Hold 2026-11-04 Building track record
UBS - Reiterated
Buy → Buy 2026-11-04 33% win rate (6 calls)
Scotiabank - Reiterated
Sector Outperform → Sector Outperform 2026-11-04 20% win rate (5 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-11-04 Building track record
JP Morgan - Reiterated
Neutral → Neutral 2026-11-04 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
26/30
Consensus clarity
17/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →